Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer

121512 (MedPage Today) — CHICAGO — Men with metastatic castration-sensitive prostate cancer (mCSPC) and DNA repair alterations had significantly longer progression-free survival (PFS) with a targeted drug plus an androgen receptor pathway inhibitor…

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top